
Core Viewpoint - Aclarion, Inc. has successfully closed a public offering of 5,175,000 units, raising approximately $3.0 million before expenses, to support its healthcare technology initiatives focused on chronic low back pain [1][2]. Group 1: Offering Details - Each unit in the offering consists of one share of common stock (or one pre-funded warrant) and two common warrants, with a public offering price of $0.58 per unit [1]. - The common warrants are immediately exercisable at a price of $0.58 per share and will expire five years from the date of issuance [1]. - The offering was conducted under a registration statement declared effective by the SEC on February 26, 2024, and was made only by means of a prospectus [2]. Group 2: Company Overview - Aclarion is a healthcare technology company utilizing Magnetic Resonance Spectroscopy (MRS) and proprietary algorithms to assist physicians in identifying chronic low back pain [4]. - The company's primary product, Nociscan, is a SaaS platform designed to noninvasively differentiate between painful and non-painful discs in the lumbar spine, providing critical insights for treatment optimization [4].